Viral Genome Sequencing
Our Viral Genome Sequencing service is one of several specialized applications within
our Next-Generation Sequencing (NGS) service portfolio. We deliver deep sequencing coverage,
de novo assemblies, and highest possible data quality at the lowest cost. As user-provided input material, we are currently
accepting double-stranded DNA and double-stranded cDNA.
We are offering this service on a weekly basis.
Start of Next Service Cycle:
Capacity for nonCOVID-19 samples remains low. Turnaround times have been extended 2-4 weeks while we adhere to social distancing guidelines to keep our staff safe. Thank you for your patience and be well!
Individual samples must be received
at the core facility
no later than 4 pm on Wednesday, . If you are using one of our dropbox locations for sample delivery, please place the order in the cooler by Wednesday mid-morning to ensure timely delivery.
If you should miss the deadline or if the total customer order volume exceeds
our current production capacity, your samples will be entered into the queue and
processed in the subsequent run. Results for all samples processed in our weekly run will
be available within 8 to 9 business days after the start of the service cycle.
Full 96-well plates can be submitted on any business day and will be processed on a first come, first serve basis. The waiting time
in queue depends on the total volume of plate orders and our processing capacity. Please
contact us at least 5 business days before your sample plate
arrives at our core facility so that we can schedule your project in a timely manner and process it as quickly as possible.
- Complete characterization of viral genomes
- Suitable for double-stranded DNA (or double-stranded cDNA) as input material
- No reference sequence required
- Independent of sequencing primers
- Cost-effective high-throughput sequencing
- Sample multiplexing using validated indices
- Fast turnaround time
IMPORTANT BIOSAFETY INFORMATION !
The MGH CCIB DNA Core presently can only accept samples for sequencing that are exempt from regulation under the current NIH Guidelines for Research Involving Recombinant or Synthetic DNA Molecules under Section III-F-2, covering nucleic acids that are not in organisms, cells, or viruses and that have not been modified or manipulated (e.g., encapsulated into synthetic or natural vehicles) to render them capable of penetrating cellular membranes.
If you have samples that do not meet this criterion you must contact the Core prior to submission.
For detailed sample preparation and submission requirements, please visit our Sample Submission Guidelines.
Please contact us to discuss your specific project needs.